Sera were randomly selected from two previously studied cohorts to investigate the immunogenicity of two doses10 or booster doses11 of COVID-19 vaccines. The first study had sera collected 3–5 weeks after the second dose of CoronaVac (28 d between the first and second dose) or BNT162b2 vaccine (21 d between first and second dose)10. The second cohort had sera collected 3–5 weeks after booster vaccination of individuals vaccinated with CoronaVac who were given a third dose of CoronaVac (the interval between the second and third vaccine dose was 61–160 d; 17 of them were also included in the previous two-dose CoronaVac study) or BNT162b2 (interval between the second and third vaccine dose was 51–141 d; 9 of them were also included in the previous two-dose CoronaVac study)11.
A third group consisted of individuals vaccinated with BNT162b2 receiving a third dose of BNT162b2 (180–234 d after the second dose; 4 of them were included in the previous two-dose BNT162b2 study)
with serum collected 3–5 weeks after the third vaccine dose. None of these individuals had a previous history of SARS-CoV-2 infection confirmed with negative IgG to SARS-CoV-2 receptor-binding domain antibody15 in the prefirst vaccine dose serum.
其實正常Paper嘅Methodology一定有寫
不過有冇人睇完先9up係另一回事
source:
https://www.nature.com/articles/s41591-022-01704-7#Sec2